Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
216 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Rhinitis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H2 2015', provides an overview of the Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Allergic Rhinitis Overview 9 Therapeutics Development 10 Pipeline Products for Allergic Rhinitis - Overview 10 Pipeline Products for Allergic Rhinitis - Comparative Analysis 11 Allergic Rhinitis - Therapeutics under Development by Companies 12 Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16 Allergic Rhinitis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Allergic Rhinitis - Products under Development by Companies 20 Allergic Rhinitis - Products under Investigation by Universities/Institutes 25 Allergic Rhinitis - Companies Involved in Therapeutics Development 26 3M Drug Delivery Systems 26 3SBio Inc. 27 Accolade Pharma LLC 28 Adamis Pharmaceuticals Corporation 29 AFFiRiS AG 30 ALK-Abello A/S 31 Ampio Pharmaceuticals, Inc. 32 AnaptysBio, Inc. 33 Axikin Pharmaceuticals, Inc. 34 BioTech Tools s.a. 35 Chong Kun Dang Pharmaceutical Corp. 36 ELORAC, Inc. 37 FAES Farma SA 38 Fountain Biopharma Inc. 39 GenMont Biotech Inc. 40 GlaxoSmithKline Plc 41 Glenmark Pharmaceuticals Ltd. 42 GlycoMar Limited 43 HAL Allergy BV 44 Hanmi Pharmaceuticals, Co. Ltd. 45 Hisamitsu Pharmaceutical Co., Inc. 46 Johnson & Johnson 47 Laboratorios LETI S.L. 48 Ligand Pharmaceuticals, Inc. 49 Marinomed Biotechnologie GmbH 50 Merck & Co., Inc. 51 Mitsubishi Tanabe Pharma Corporation 52 Nektar Therapeutics 53 NeoPharm Co., Ltd. 54 Novartis AG 55 Nuvo Research Inc. 56 Oxagen Limited 57 Panmira Pharmaceuticals, LLC. 58 Pfizer Inc. 59 Protectimmun GmbH 60 Regeneron Pharmaceuticals, Inc. 61 Revance Therapeutics, Inc. 62 Roxall Medizin GmbH 63 Sanofi 64 Shionogi & Co., Ltd. 65 Stallergenes S.A. 66 VentiRx Pharmaceuticals, Inc. 67 Xencor, Inc. 68 Ziarco Pharma Ltd 69 Allergic Rhinitis - Therapeutics Assessment 70 Assessment by Monotherapy Products 70 Assessment by Combination Products 71 Assessment by Target 72 Assessment by Mechanism of Action 74 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 80 (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 80 (fluticasone furoate + levocabastine hydrochloride) - Drug Profile 81 (levocabastine hydrochloride + mometasone furoate) - Drug Profile 82 (montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 83 854-A - Drug Profile 84 Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 85 Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 86 Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 87 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 88 Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 89 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 90 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 92 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 93 AM-211 - Drug Profile 94 AM-461 - Drug Profile 96 Ampion - Drug Profile 98 ANB-020 - Drug Profile 100 APC-3000 - Drug Profile 101 Arabinogalactan - Drug Profile 102 bepotastine besylate - Drug Profile 103 beta-escin - Drug Profile 105 bilastine - Drug Profile 107 budesonide - Drug Profile 109 CBP-174 - Drug Profile 110 cidoxepin hydrochloride - Drug Profile 111 clustoid wiesenlieschgras - Drug Profile 112 daxibotulinumtoxin A - Drug Profile 113 desloratadine - Drug Profile 115 Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile 117 esketamine hydrochloride - Drug Profile 118 FB-825 - Drug Profile 121 fevipiprant - Drug Profile 122 fexofenadine hydrochloride - Drug Profile 124 GLY-079 - Drug Profile 125 GLY-145 - Drug Profile 126 GMNL-32 - Drug Profile 127 gp-ASIT - Drug Profile 128 GSK-2245035 - Drug Profile 130 GSP-301 - Drug Profile 132 HCP-1406 - Drug Profile 133 house dust mite [Dermatophagoides pteronyssinus + Dermatophagoides farinae] allergen extract - Drug Profile 134 HP-3060 - Drug Profile 136 Lactococcus lactis G121 - Drug Profile 137 levocabastine hydrochloride - Drug Profile 138 motolimod - Drug Profile 139 nasapaque - Drug Profile 141 NKTR-125 - Drug Profile 142 NPB-3 - Drug Profile 143 OC-2417 - Drug Profile 144 pentosan polysulfate sodium - Drug Profile 145 PF-06444752 - Drug Profile 146 PF-06444753 - Drug Profile 147 rE58 - Drug Profile 148 REGN-19081909 - Drug Profile 149 S-555739 - Drug Profile 150 Small Molecule for Allergic Rhinitis - Drug Profile 151 Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 152 Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 153 Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 154 Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile 155 STG-120 - Drug Profile 156 STG-320 - Drug Profile 157 Vaccine for Allergic Rhinitis and Allergic Asthma - Drug Profile 159 Vaccine for Allergic Rhinitis and Asthma - Drug Profile 160 VTX-1463 - Drug Profile 161 WF-10 - Drug Profile 162 WF-10 liposomal - Drug Profile 164 XmAb-7195 - Drug Profile 165 Zafi-3 - Drug Profile 166 ZPL-868087 - Drug Profile 167 Allergic Rhinitis - Recent Pipeline Updates 168 Allergic Rhinitis - Dormant Projects 191 Allergic Rhinitis - Discontinued Products 200 Allergic Rhinitis - Product Development Milestones 203 Featured News & Press Releases 203 Appendix 210 Methodology 210 Coverage 210 Secondary Research 210 Primary Research 210 Expert Panel Validation 210 Contact Us 210 Disclaimer 211
List of Tables
Number of Products under Development for Allergic Rhinitis, H2 2015 15 Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2015 16 Number of Products under Development by Companies, H2 2015 18 Number of Products under Development by Companies, H2 2015 (Contd..1) 19 Number of Products under Development by Companies, H2 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2015 21 Comparative Analysis by Late Stage Development, H2 2015 22 Comparative Analysis by Clinical Stage Development, H2 2015 23 Comparative Analysis by Early Stage Development, H2 2015 24 Products under Development by Companies, H2 2015 25 Products under Development by Companies, H2 2015 (Contd..1) 26 Products under Development by Companies, H2 2015 (Contd..2) 27 Products under Development by Companies, H2 2015 (Contd..3) 28 Products under Development by Companies, H2 2015 (Contd..4) 29 Products under Investigation by Universities/Institutes, H2 2015 30 Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2015 31 Allergic Rhinitis - Pipeline by 3SBio Inc., H2 2015 32 Allergic Rhinitis - Pipeline by Accolade Pharma LLC, H2 2015 33 Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015 34 Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2015 35 Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2015 36 Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 37 Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H2 2015 38 Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2015 39 Allergic Rhinitis - Pipeline by BioTech Tools s.a., H2 2015 40 Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 41 Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2015 42 Allergic Rhinitis - Pipeline by FAES Farma SA, H2 2015 43 Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2015 44 Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H2 2015 45 Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2015 46 Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 47 Allergic Rhinitis - Pipeline by GlycoMar Limited, H2 2015 48 Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2015 49 Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 50 Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 51 Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2015 52 Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2015 53 Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 54 Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2015 55 Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2015 56 Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 57 Allergic Rhinitis - Pipeline by Nektar Therapeutics, H2 2015 58 Allergic Rhinitis - Pipeline by NeoPharm Co., Ltd., H2 2015 59 Allergic Rhinitis - Pipeline by Novartis AG, H2 2015 60 Allergic Rhinitis - Pipeline by Nuvo Research Inc., H2 2015 61 Allergic Rhinitis - Pipeline by Oxagen Limited, H2 2015 62 Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2015 63 Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2015 64 Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2015 65 Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 66 Allergic Rhinitis - Pipeline by Revance Therapeutics, Inc., H2 2015 67 Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2015 68 Allergic Rhinitis - Pipeline by Sanofi, H2 2015 69 Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2015 70 Allergic Rhinitis - Pipeline by Stallergenes S.A., H2 2015 71 Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 72 Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2015 73 Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H2 2015 74 Assessment by Monotherapy Products, H2 2015 75 Assessment by Combination Products, H2 2015 76 Number of Products by Stage and Target, H2 2015 78 Number of Products by Stage and Mechanism of Action, H2 2015 80 Number of Products by Stage and Route of Administration, H2 2015 82 Number of Products by Stage and Molecule Type, H2 2015 84 Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H2 2015 173 Allergic Rhinitis - Dormant Projects, H2 2015 196 Allergic Rhinitis - Dormant Projects (Contd..1), H2 2015 197 Allergic Rhinitis - Dormant Projects (Contd..2), H2 2015 198 Allergic Rhinitis - Dormant Projects (Contd..3), H2 2015 199 Allergic Rhinitis - Dormant Projects (Contd..4), H2 2015 200 Allergic Rhinitis - Dormant Projects (Contd..5), H2 2015 201 Allergic Rhinitis - Dormant Projects (Contd..6), H2 2015 202 Allergic Rhinitis - Dormant Projects (Contd..7), H2 2015 203 Allergic Rhinitis - Dormant Projects (Contd..8), H2 2015 204 Allergic Rhinitis - Discontinued Products, H2 2015 205 Allergic Rhinitis - Discontinued Products (Contd..1), H2 2015 206 Allergic Rhinitis - Discontinued Products (Contd..2), H2 2015 207
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
